Mpm Bioimpact LLC
Mpm Bioimpact LLC reported 37 holdings worth US$1.35B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Mpm Bioimpact LLC reported 37 holdings worth US$1.35B as of Sep 30, 2026. Largest: Cullinan Therapeutics, Inc., Aktis Oncology, Inc. and Travere Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 37
- Value as reported
- US$1.35B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Cullinan Therapeutics, Inc. | 9.72M | US$149M | 11.1% |
| Aktis Oncology, Inc. | 4.84M | US$94.2M | 7.0% |
| Travere Therapeutics, Inc. | 1.09M | US$64.1M | 4.8% |
| Edgewise Therapeutics, Inc. | 1.58M | US$64M | 4.7% |
| Dyne Therapeutics, Inc. | 3.21M | US$51.7M | 3.8% |
| Corcept Therapeutics Incorporated | 422K | US$48.6M | 3.6% |
| Relay Therapeutics, Inc. | 2.37M | US$42.8M | 3.2% |
| Trevi Therapeutics, Inc. | 2.98M | US$42.7M | 3.2% |
| Iovance Biotherapeutics, Inc. | 2.84M | US$42M | 3.1% |
| Liquidia Corporation | 1.34M | US$40.6M | 3.0% |
| Natera, Inc. | 90,585 | US$37.4M | 2.8% |
| Immunocore Holdings plc | 1.2M | US$36.4M | 2.7% |
| DBV Technologies SA | 3.04M | US$35.8M | 2.7% |
| Taysha Gene Therapies, Inc. | 7.26M | US$35.4M | 2.6% |
| Abivax SA | 328K | US$32.5M | 2.4% |
| Vir Biotechnology, Inc. | 2.81M | US$31.4M | 2.3% |
| Adlai Nortye Group Ltd. | 1.96M | US$31.3M | 2.3% |
| Verastem, Inc. | 3.85M | US$31M | 2.3% |
| Odyssey Therapeutics, Inc. | 1.29M | US$28.6M | 2.1% |
| Tarsus Pharmaceuticals, Inc. | 353K | US$27.7M | 2.1% |
| Palvella Therapeutics, Inc. | 198K | US$27.3M | 2.0% |
| Aclaris Therapeutics, Inc. | 5.18M | US$27.2M | 2.0% |
| Oruka Therapeutics, Inc. | 300K | US$25M | 1.9% |
| ORIC Pharmaceuticals, Inc. | 1.82M | US$24.5M | 1.8% |
| Stoke Therapeutics, Inc. | 925K | US$24.1M | 1.8% |
| Belite Bio, Inc. | 133K | US$22.7M | 1.7% |
| Neurogene Inc. | 772K | US$21.5M | 1.6% |
| Zura Bio Limited | 4.45M | US$18.5M | 1.4% |
| Annexon, Inc. | 4.29M | US$18.1M | 1.3% |
| Monte Rosa Therapeutics, Inc. | 1.13M | US$13.4M | 1.00% |
| BioAge Labs, Inc. | 1.86M | US$13.2M | 0.98% |
| Corbus Pharmaceuticals Holdings, Inc. | 1.67M | US$11.4M | 0.84% |
| Bright Minds Biosciences Inc. | 196K | US$9.75M | 0.72% |
| First Tracks Biotherapeutics, Inc. | 254K | US$9.02M | 0.67% |
| Entrada Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Forte Biosciences, Inc. | 0 | US$0 | 0.00% |
| Revolution Medicines, Inc. | 0 | US$0 | 0.00% |
| Syndax Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Ultragenyx Pharmaceutical Inc. | 0 | US$0 | 0.00% |
| Werewolf Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Alumis Inc. | 0 | US$0 | 0.00% |
| Context Therapeutics Inc. | 0 | US$0 | 0.00% |
| Dianthus Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related